LGR5 and neoplasm: Administration of the EREG mAb following irinotecan treatment delayed growth of subcutaneous patient-derived xenografts enriched for LGR5 as well as decreased the number and size of metastatic tumor nodules after IV injection of the patient-derived LGR5+ CRC cells [105].